- Home
- MYRG vs CELC Comparison
MYRG vs CELC Comparison
Compare MYRG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYRG
- CELC
- Stock Information
- Founded
- MYRG 1891
- CELC 2011
- Country
- MYRG United States
- CELC United States
- Employees
- MYRG N/A
- CELC N/A
- Industry
- MYRG Water Sewer Pipeline Comm & Power Line Construction
- CELC Medical Specialities
- Sector
- MYRG Industrials
- CELC Health Care
- Exchange
- MYRG Nasdaq
- CELC Nasdaq
- Market Cap
- MYRG 2.9B
- CELC 2.3B
- IPO Year
- MYRG N/A
- CELC 2017
- Fundamental
- Price
- MYRG $205.38
- CELC $48.89
- Analyst Decision
- MYRG Buy
- CELC Strong Buy
- Analyst Count
- MYRG 7
- CELC 6
- Target Price
- MYRG $189.83
- CELC $63.00
- AVG Volume (30 Days)
- MYRG 277.8K
- CELC 1.0M
- Earning Date
- MYRG 10-29-2025
- CELC 11-13-2025
- Dividend Yield
- MYRG N/A
- CELC N/A
- EPS Growth
- MYRG 63.05
- CELC N/A
- EPS
- MYRG 4.77
- CELC N/A
- Revenue
- MYRG $3,451,783,000.00
- CELC N/A
- Revenue This Year
- MYRG $8.11
- CELC N/A
- Revenue Next Year
- MYRG $6.19
- CELC N/A
- P/E Ratio
- MYRG $43.17
- CELC N/A
- Revenue Growth
- MYRG N/A
- CELC N/A
- 52 Week Low
- MYRG $97.72
- CELC $7.58
- 52 Week High
- MYRG $220.02
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- MYRG 62.26
- CELC 48.71
- Support Level
- MYRG $193.61
- CELC $47.43
- Resistance Level
- MYRG $205.04
- CELC $49.58
- Average True Range (ATR)
- MYRG 7.91
- CELC 2.81
- MACD
- MYRG 1.00
- CELC -0.84
- Stochastic Oscillator
- MYRG 82.66
- CELC 42.55
About MYRG MYR Group Inc.
MYR Group Inc is a U.S.-based holding company that provides specialty electrical construction services through its subsidiaries. The company operates through two segments. The transmission and distribution segment provides designing, engineering, procurement, construction, upgrade, maintenance, and repair services on transmission and distribution networks and substation facilities. The commercial and industrial segment provides services such as the design, installation, maintenance, and repair of commercial and industrial wiring, installation of traffic networks, and the installation of bridges. MYR Group generates the majority of its sales from the United States and Canada.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.